David Scadden insider trades

Open-market stock purchases and sales by David Scadden, Director at Agios Pharmaceuticals, Inc, from SEC Form 4 filings since May 27, 2017.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -61%.

Recent trades

DateStockTradeValue
Jun 18, 2026AGIO Agios Pharmaceuticals, IncBought (not open market)—
Jun 18, 2026AGIO Agios Pharmaceuticals, IncBought (not open market)—
Jun 18, 2026AGIO Agios Pharmaceuticals, IncBought (not open market)—
Jun 17, 2026EDIT Editas Medicine, IncBought (not open market)—
Nov 12, 2025AGIO Agios Pharmaceuticals, IncSold$8.8K
Nov 12, 2025AGIO Agios Pharmaceuticals, IncBought (not open market)—
Oct 8, 2025AGIO Agios Pharmaceuticals, IncSold$8.2K
Oct 8, 2025AGIO Agios Pharmaceuticals, IncBought (not open market)—

Companies traded

  • AGIO Agios Pharmaceuticals, Inc: 1 buy, 6 sales, last Jun 18, 2026
  • EDIT Editas Medicine, Inc: other filings, last Jun 17, 2026
  • CARM Carisma Therapeutics Inc: other filings, last Jul 1, 2024
  • MGTA Magenta Therapeutics, Inc: 1 buy, last Jun 28, 2022

Get free alerts when David Scadden files a new trade →